FEBRUARY 4, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early detection of cancer. The patent, titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 […]
OCTOBER 23, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is affiliated with the federal Department of Veterans Affairs (VA) health care system, will be a clinical collection site for the Company’s test validation trial of CyPath® Lung, a non-invasive […]
OCTOBER 10, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced a licensing agreement with Precision Pathology Services for the continued development and commercial sale of CyPath® Lung as a Laboratory Developed Test (LDT) for the diagnosis of early-stage lung cancer. bioAffinity currently is conducting a test validation trial of CyPath® […]
SEPTEMBER 18, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, will be a clinical collection site for the Company’s test validation trial of CyPath® Lung, a non-invasive test for the early detection of lung cancer. The […]
JULY 31, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin Y. Meghji, managing partner of M-III Partners L.P. (M-III), to its Board of Directors. “As managing partner of a corporate advisory firm that helps its clients maximize performance and create long-term […]
JULY 17, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an advanced flow cytometry test for the early detection of lung cancer. Recruitment is ongoing for patients diagnosed with lung cancer and individuals at high risk for the disease […]